Sonnet Biotherapeutics' Previously Announced Interim Data From The Sb101 Trial Of SON-1010 (Il12- FHAB), Will Be Presented By Dr. Sant Chawla, A Key Opinion Leader In The Field Of Sarcoma Research, At The Upcoming Connective Tissue Oncology Society Annual
Benzinga Newsdesk - Oct 17, 2023, 8:07AM